Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-13 02:01 UTC

BIOMED PULSE

Sunday, July 13, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now reached 1,460 confirmed cases and 452 deaths as of July 1, making it the dominant global health emergency — and the PARTNERS clinical trial just opened patient enrolment in DRC to find the first effective treatments. Mood: urgent but cautiously active; science is moving fast to catch a fast-moving outbreak. [1] [2]

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS — DRC AND UGANDA (PHEIC)

  • As of July 1, 2026, DRC has recorded 1,460 confirmed cases and 452 deaths from Bundibugyo virus disease (BVD), with sustained transmission and continuing geographic spread. [1]
  • WHO declared the DRC/Uganda BVD outbreak a Public Health Emergency of International Concern (PHEIC) on May 17, 2026; it does not yet meet criteria for a pandemic emergency. [3] [4]
  • Africa CDC and WHO launched a joint continental response plan on June 5, 2026, seeking to raise USD 518 million to support African countries against BVD. [5]
  • WHO issued its first comprehensive filovirus clinical management guidelines on June 17, 2026, covering all Ebola and Marburg virus types. [6]
  • On July 2, 2026, WHO added the first molecular diagnostic test for Bundibugyo virus to its Emergency Use Listing, enabling rapid genetic detection in blood samples. [7]
  • The PARTNERS clinical trial opened patient enrolment in DRC on July 2, 2026, aiming to identify the first effective treatments specifically for Bundibugyo virus disease. [2]
  • CDC issued its most recent statement on the DRC/Uganda Ebola outbreak on July 10, 2026, and continues to maintain enhanced airport screening at Washington-Dulles and Atlanta. [8] [9] [10]

WEST NILE VIRUS — UNITED STATES

  • CDC reported an early and record-breaking West Nile virus season heading into the July 4 holiday weekend, urging Americans to use mosquito repellent and protective clothing.

NIPAH VIRUS — INDIA (KERALA)

  • On June 11, 2026, Kerala State confirmed one laboratory-confirmed Nipah virus (NiV) infection in Kozhikode district; the adult male patient presented with neurological symptoms and was hospitalized on June 10.
  • Earlier in 2026, two healthcare workers at a private hospital in Barasat, West Bengal, India were confirmed with NiV on January 30, and one case was confirmed in Bangladesh's Rajshahi Division on February 6.

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP (MULTI-COUNTRY)

  • As of the fifth WHO Disease Outbreak News report dated July 2, 2026, the Andes hantavirus (ANDV) cluster linked to cruise ship M/V Hondius continues to be monitored; the outbreak originated May 2, 2026 with severe respiratory illness cases aboard the vessel.
  • CDC's most recent hantavirus response transcript was issued June 24, 2026.

AVIAN INFLUENZA A(H9N2) — ITALY

  • Italy notified WHO on March 21, 2026 of a human H9N2 case in an adult male returning from Senegal; next-generation sequencing confirmed Influenza A(H9N2).

MPOX — RECOMBINANT STRAIN (GLOBAL)

  • WHO reported in February 2026 two human cases of a recombinant MPXV strain combining genomic elements of clades Ib and IIb, a known but closely watched natural recombination process.

YELLOW FEVER — AMERICAS AND AFRICA

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; transmission activity carried over from an elevated 2025 Americas season into 2026.

MEASLES — BANGLADESH

  • Bangladesh notified WHO on April 4, 2026 of 19,161 suspected measles cases and 2,897 laboratory-confirmed cases affecting 58 of 64 districts across all eight divisions.

E. COLI — FROZEN BLUEBERRIES (UNITED STATES)

  • CDC issued a food safety alert on July 7, 2026 warning consumers not to eat recalled frozen blueberries linked to a multistate E. coli outbreak.

SALMONELLA — FROZEN SPROUTED BEANS (UNITED STATES)

  • CDC warns that 11 people across 10 states have been sickened with the same Salmonella strain linked to frozen sprouted beans, per an alert dated July 17, 2026 (appearing in the data feed).

🧬 LONGEVITY & AGING

NAD-PLUS HOMEOSTASIS AND AGED BONE REPAIR

  • A study published in Bioactive Materials (June 27, 2026) describes a senescent metabolism-modulating hierarchical scaffold designed to restore NAD-plus homeostasis and redox balance, targeting cellular senescence in aging bone tissue to improve repair.
  • NAD-plus decline is a hallmark of aging biology; restoring it in bone microenvironments addresses both senescent cell accumulation and impaired tissue regeneration in older adults.

KAEMPFEROL FROM MORINGA AND LIFESPAN IN DROSOPHILA

  • Research published in Toxicology Reports (June 25, 2026) found that kaempferol derived from Moringa oleifera increased longevity and reduced efavirenz-induced functional senescence in Drosophila melanogaster, suggesting the flavonoid may mitigate drug-accelerated aging pathways.

DELIRIUM AS A BRIDGE FROM INFECTION TO DEMENTIA

  • Two linked commentaries in Lancet Healthy Longevity (Sipilä and Kivimäki; Penfold, Jiwaji, and MacLullich) frame delirium following severe infection as a potential missing mechanistic link in the pathway from acute illness to subsequent dementia in older adults.
  • The hypothesis is clinically significant because it suggests that better delirium prevention and management in hospitalized older patients could reduce long-term dementia incidence.

HYPERTENSION AND FRAILTY IN MIDDLE-AGED AND OLDER ADULTS — INDIA

  • A letter in Blood Pressure (July 7, 2026) by Goyal, Kalra, and Nagpal responds to data from the Longitudinal Ageing Study in India, reinforcing associations between uncontrolled hypertension and accelerated frailty progression in middle-aged and older Indian adults.

TAU, EMERIN, AND NEURONAL CYTOSKELETAL REMODELING

  • Research published in Nucleus (July 7, 2026) by Sohn et al. links elevated nuclear mechanosensory protein emerin to tau-induced cytoskeletal remodeling in neurons, connecting nuclear mechanotransduction to a key aging-related neurodegenerative pathway.

ACTIVITY RESTRICTION, CEREBROVASCULAR MORTALITY, AND LONG-TERM CARE — JAPAN

  • An ecological panel study across Japan's 47 prefectures (2013-2022) published in Dialogues Health found that structural physical activity restriction was associated with higher cerebrovascular and diabetes mortality and greater long-term care intensity, with a COVID-19 counterfactual analysis reinforcing the finding.

SOCIAL DETERMINANTS OF HEALTHY LONGEVITY — ANALYSIS

  • A comprehensive analysis published in Problemy Sotsialnoi Gigieny (Amonova et al.) examines medical and social determinants of healthy longevity, identifying prevention strategies targeting education, socioeconomic conditions, and healthcare access as key levers for extending healthspan.

CANCER PROJECTIONS — WHO WARNING

  • WHO reported on July 8, 2026 that new global cancer cases are projected to nearly double by 2050, from an estimated 20.6 million new cases and close to 10 million deaths annually today — framing cancer as an accelerating threat to population longevity.

NITRATE SUPPLEMENTATION TRIAL FOR OLDER ADULTS (CLINICALTRIALS)

  • ClinicalTrials.gov lists NCT07572266, titled "Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults," investigating whether dietary nitrate can amplify exercise's multipotent benefits against aging hallmarks including physical, metabolic, and mental impairments that compromise healthspan.

💊 NEW CURES & APPROVALS

TRUTAKNA (ATACIEPT-VYMJ) — VERA THERAPEUTICS INC.

  • OpenFDA records an original approval (ORIG AP) for TRUTAKNA, sponsored by Vera Therapeutics Inc., with active ingredient ataciept-VYMJ (BLA 761486); ataciept is a fusion protein that blocks both APRIL and BAFF survival signals exploited by autoreactive B cells, relevant to IgA nephropathy and related autoimmune conditions.

RINVOQ LQ (UPADACITINIB) — ABBVIE

  • OpenFDA records a supplemental approval (SUPPL AP) for RINVOQ LQ, sponsored by AbbVie, active ingredient upadacitinib (NDA 218347); upadacitinib is a selective JAK1 inhibitor approved across multiple inflammatory indications including rheumatoid arthritis, atopic dermatitis, and Crohn's disease.

VARENICLINE TARTRATE — SOMERSET THERAPS LLC

  • OpenFDA records an original approval (ORIG AP) for varenicline tartrate (ANDA 219382) from Somerset Theraps LLC; varenicline is a partial nicotinic acetylcholine receptor agonist used for smoking cessation.

RYALTRIS (MOMETASONE FUROATE / OLOPATADINE HCl) — GLENMARK SPECIALTY

  • OpenFDA records a supplemental approval (SUPPL AP) for RYALTRIS nasal spray (NDA 211746), a dual-action intranasal combination of corticosteroid mometasone furoate and antihistamine olopatadine hydrochloride for allergic rhinitis.

INBRIJA (LEVODOPA) — MERZ

  • OpenFDA records a supplemental approval (SUPPL AP) for INBRIJA (NDA 209184), sponsored by Merz; INBRIJA is an inhaled levodopa formulation for off episodes in Parkinson's disease.

NOTE: openFDA approval dates are listed as invalid in the current data feed; the above reflect active approval actions without confirmed exact dates. These entries are informational only and not medical advice.

🧪 CLINICAL TRIALS

PARTNERS TRIAL — BUNDIBUGYO VIRUS DISEASE TREATMENTS (DRC)

  • The WHO-supported PARTNERS clinical trial opened patient enrolment on July 2, 2026 in DRC, aiming to be the first trial to identify effective treatments for Ebola disease caused by Bundibugyo virus. [2]
  • This is a landmark milestone: no validated therapeutics exist for Bundibugyo virus disease, making this trial a critical scientific and humanitarian priority during an active PHEIC. [2]

IL-12 GENETICALLY ENGINEERED MYELOID CELLS — SOLID TUMORS (NCT07672483)

  • ClinicalTrials.gov lists a study testing IL-12 genetically engineered myeloid cells (IL-12 GEMys) in participants with relapsed or refractory solid tumors; the approach arms immune myeloid cells found naturally in tumors with IL-12 to boost anti-tumor killing.

BRINCIDOFOVIR FOR PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (NCT07511049)

  • A pilot study on ClinicalTrials.gov is testing intravenous brincidofovir as an antiviral for progressive multifocal leukoencephalopathy (PML), a rare fatal JC-virus brain infection that strikes immunocompromised patients with no currently approved treatment.

177Lu-DOTA-EB-TATE FOR ONCOCYTIC THYROID CANCER (NCT06991738)

  • ClinicalTrials.gov lists a trial testing radioactive drug 177Lu-DOTA-EB-TATE, which targets a somatostatin receptor protein overexpressed on oncocytic (Hurthle cell) thyroid cancer cells, a rare disease with few existing treatment options.

ADJUVANT NITRATE TO BOOST EXERCISE BENEFITS IN OLDER ADULTS (NCT07572266)

  • This ClinicalTrials.gov aging study investigates dietary nitrate as an adjuvant to amplify exercise-induced mitigation of biological aging hallmarks, targeting physical, metabolic, and cognitive healthspan outcomes in older adults.

📢 PUBLIC HEALTH

UNSAFE FOOD — WHO GLOBAL BURDEN UPDATE

  • WHO reported on June 3, 2026 that unsafe food causes 866 million illnesses and 1.5 million deaths annually worldwide; children under five face almost three times the illness risk of older children and adults.

CANCER DOUBLES BY 2050 — WHO CALL FOR ACTION

  • WHO's July 8, 2026 report projects nearly double the current annual cancer burden by 2050, with more than 26,000 cancer deaths every day already; WHO is calling for urgent global investment in prevention, early detection, and treatment.

MORINGA LEAF PRODUCTS — ONGOING SALMONELLA ALERT (UNITED STATES)

  • As of May 27, 2026, CDC issued a growing alert linking multiple Salmonella outbreaks and illnesses to moringa leaf products, including extensively drug-resistant strains; consumers are urged to avoid moringa powder capsules and supplements under recall.

TICK BITE ER VISITS ABOVE NORMAL — CDC (UNITED STATES)

  • CDC data as of April 23, 2026 show weekly emergency-room visits for tick bites are running higher than usual for this point in the season; public health resources are available to help families protect themselves.

WORLD CUP 2026 HEALTH ACTIVATION — CDC

  • CDC has activated a World Cup 2026 public health monitoring effort, tracking health threats related to mass gathering travel alongside the ongoing Ebola response.

WHO PANDEMIC AGREEMENT — PATHOGEN ACCESS ANNEX STILL UNFINISHED

  • In an open letter dated June 15, 2026, WHO Director-General Tedros and co-signatories called on G7, G20, and BRICS leaders to finalize the Pathogen Access and Benefit Sharing (PABS) annex of the WHO Pandemic Agreement, warning the world must finish what it started.

U.S. WHO WITHDRAWAL COMPLETE

  • The United States completed its formal withdrawal from WHO on January 22, 2026, citing COVID-19 failures and politicization, with a stated shift toward bilateral health engagement.

BIOMED PULSE is an informational briefing grounded in official public health and scientific sources. Nothing here constitutes medical advice. Consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Patient enrolment begins in a scientific trial to identify the… — WHO News
  3. Epidemic of Ebola Disease caused by Bundibugyo virus in the De… — WHO News
  4. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  5. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  6. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  7. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  8. CDC Statement on Ebola Outbreak in the Democratic Republic of … — CDC Newsroom
  9. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  10. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260713-02-v26 · 2026-07-13 02:01 UTC · pulse.uzylab.com

Read next